<DOC>
	<DOCNO>NCT00615134</DOCNO>
	<brief_summary>This 2 arm study ass efficacy safety new regimen Fuzeon + optimize background antiretroviral treatment , Fuzeon-naive HIV-1 infect patient virological failure . Eligible patient randomize recei either new optimized treatment alone , optimized treatment + Fuzeon 90mg s. c. twice daily , determine effect 3 month induction Fuzeon.It possible patient receive several additional 3 month period F uzeon , case new virological failure . The anticipated time study tre atment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>INNOVE Study : A Study 3 Months Induction With Fuzeon ( Enfuvirtide ) + Optimized Background ( OB ) Versus OB Alone HIV-1 Infected Patients With Virological Failure .</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; HIV1 infection , virologic failure ; stable HAART &gt; 4 week , viral load &gt; 1000 RNA copies/mL ; Fuzeonnaive . coinfection HIV2 ; active opportunistic infection 4 week prior screen ; cirrhosis severe liver failure ; severe renal disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>treatment experience</keyword>
</DOC>